查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595650

干癣药物市场：按治疗层级、按治疗类型、按作用机制、按给药途径、按分销渠道、按应用 - 2025-2030 年全球预测

Psoriasis Drugs Market by Therapeutic Class, Type of Treatment, Mechanism of Action, Route of Administration, Distribution Channel, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年干癣治疗市场价值为96.7亿美元，预计到2024年将达到108.3亿美元，复合年增长率为12.07%，到2030年将达到214.8亿美元。

干癣药物的范围包括一系列旨在控制和缓解干癣是一种慢性自体免疫疾病，其特征是皮肤细胞快速增殖，导致脱皮和发炎。全球干癣盛行率不断上升，影响数百万人并极大影响生活质量，这凸显了对这些药物的需求。治疗方法包括生物製药、口服全身治疗和局部治疗，每种治疗均根据干癣的严重程度和类型进行客製化。最终的使用范围主要是在医院、诊所和居家医疗环境中，由于其复杂性，生物製药通常在临床环境中使用。

主要市场统计
基准年[2023] 96.7亿美元
预测年份 [2024] 108.3亿美元
预测年份 [2030] 214.8亿美元
复合年增长率（%） 12.07%

影响干癣药物市场的主要成长要素包括生物技术研究的进步，导致标靶治疗，增加医疗保健支出，以及对干癣及其治疗方案的认识不断提高。此外，处于临床试验各个阶段的不断扩大的药物管线也带来了巨大的成长机会。特别是，向以患者为中心的治疗的转变和对个人化医疗的需求正在推动市场潜力，新兴国家由于都市化和生活方式的改变导致干癣率不断上升。

然而，也存在一些挑战。生物製药治疗的高成本和药物核准的严格监管要求是主要障碍。此外，低收入地区获得药品的机会可能受到限制，进而影响市场渗透率。

创新努力可能包括开发具有成本效益的生物相似药、提高现有药物的疗效以及探索新的给药系统以提高患者的依从性。数位健康整合有很多机会，例如用于症状监测的可穿戴设备，可以促进更好的管理。该市场的特点是技术快速进步以及向更全面和患者友好的治疗方法的动态转变。利用这些创新并解决成本可及性障碍的公司有潜力推动显着成长，并在这个不断变化的市场环境中保持竞争力。

市场动态：揭示快速发展的干癣药物市场的关键市场洞察

供需的动态交互作用正在改变干癣药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 干癣盛行率增加
    • 老年人口增加以及斑块型干癣和干癣性关节炎盛行率增加
    • 干癣药物的核准流程简化
  • 市场限制因素
    • 治疗费用高
  • 市场机会
    • 干癣研究和管道药物开发
  • 市场挑战
    • 药物副作用

波特的五力战略工具驾驭干癣药物市场

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对干癣药物市场的影响

外部宏观环境因素在塑造干癣治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解干癣治疗药物市场的竞争状况

对干癣治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵干癣治疗市场供应商的绩效评估

FPNV 定位矩阵是评估干癣治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为干癣治疗药物市场的成功指明道路

对于旨在加强其在全球市场的影响力的公司来说，对干癣治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 干癣发生率增加
      • 老年人口增加，斑块型干癣和干癣性关节炎盛行率增加
      • 干癣药物的核准流程简化
    • 抑制因素
      • 治疗费用高
    • 机会
      • 干癣研究和管道药物增加
    • 任务
      • 药物副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗层级的干癣治疗药物市场

  • 白细胞介素抑制剂
  • 肿瘤坏死因子抑制剂

第七章依治疗类型分類的干癣治疗药物市场

  • 生物製药
  • 小分子全身药物
  • 热带疗法

第八章干癣治疗药物市场（依作用机转）

  • 白细胞介素抑制剂
  • PDE4抑制剂
  • TNFα抑制剂

第九章干癣治疗药物市场：依给药途径

  • 口服
  • 胃肠外的
  • 话题

第10章干癣治疗药物市场：依分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第十一章干癣治疗药物市场：依应用分类

  • 关节炎
  • 红皮病
  • 水滴
  • 间擦的
  • 指甲
  • 斑块
  • 脓疱型

第十二章美洲干癣药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十三章亚太地区干癣药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第14章欧洲、中东和非洲的干癣药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bausch Health Companies Inc.
  • Celgene Corporation
  • Dr.Reddy's Laboratories
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Leo Pharma AS
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Stiefel Laboratories Inc.
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-434CCDA051B5

The Psoriasis Drugs Market was valued at USD 9.67 billion in 2023, expected to reach USD 10.83 billion in 2024, and is projected to grow at a CAGR of 12.07%, to USD 21.48 billion by 2030.

The scope of psoriasis drugs encompasses a range of treatments designed to manage and alleviate the symptoms associated with psoriasis, a chronic autoimmune condition characterized by the rapid growth of skin cells leading to scaling and inflammation. The necessity of these drugs is underscored by the increasing prevalence of psoriasis globally, which affects millions and can significantly impact quality of life. Applications extend across various drug types including biologics, oral systemic treatments, and topical therapies, each tailored to different severities and types of psoriasis. End-use scope primarily involves hospitals, clinics, and home care settings, with biologics frequently administered in clinical settings due to their complexity.

KEY MARKET STATISTICS
Base Year [2023] USD 9.67 billion
Estimated Year [2024] USD 10.83 billion
Forecast Year [2030] USD 21.48 billion
CAGR (%) 12.07%

Key growth factors influencing the psoriasis drugs market include advancing research in biotechnology leading to targeted therapies, increased healthcare spending, and heightened awareness of psoriasis and its treatment options. Additionally, the expanding pipeline of drugs in various stages of clinical trials presents significant growth opportunities. Notably, the shift towards patient-centric care and the demand for personalized medicine boost the market's potential, as does the rising incidence of psoriasis in developing countries due to urbanization and changing lifestyles.

However, several challenges exist. High costs associated with biologic treatments and stringent regulatory requirements for drug approval pose significant barriers. Moreover, access to medications in low-income regions can be limited, affecting market penetration.

Innovation efforts could focus on developing cost-effective biosimilars, improving the efficacy of existing drugs, and exploring novel delivery systems to enhance patient compliance. There is ample opportunity in digital health integration, such as wearable devices for symptom monitoring, which can facilitate better management. The market is characterized by rapid technological advancements and dynamic shifts towards more holistic and patient-friendly treatment approaches. Companies that leverage these innovations and address the cost accessibility barriers can potentially drive substantial growth and maintain a competitive edge in this evolving market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Psoriasis Drugs Market

The Psoriasis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of psoriasis
    • Rising geriatric population coupled with growing prevalence of plaque psoriasis and psoriatic arthritis
    • Ease of process of approval of psoriasis drugs
  • Market Restraints
    • High cost of treatment
  • Market Opportunities
    • Increase in psoriasis research and pipeline drugs
  • Market Challenges
    • Side effects of the medication

Porter's Five Forces: A Strategic Tool for Navigating the Psoriasis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Psoriasis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Psoriasis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Psoriasis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Psoriasis Drugs Market

A detailed market share analysis in the Psoriasis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Psoriasis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Psoriasis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Psoriasis Drugs Market

A strategic analysis of the Psoriasis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Psoriasis Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc., Celgene Corporation, Dr.Reddy's Laboratories, Eli Lilly and Company, Johnson & Johnson Services, Inc., Leo Pharma AS, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Stiefel Laboratories Inc., Sun Pharmaceutical Industries Ltd, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Psoriasis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutic Class, market is studied across Interleukin Inhibitors and Tumor Necrosis Factor Inhibitor.
  • Based on Type of Treatment, market is studied across Biologic Drugs, Small Molecule Systemic Drugs, and Tropical Therapies.
  • Based on Mechanism of Action, market is studied across Interleukin Inhibitors, PDE4 Inhibitors, and TNF Alpha Inhibitors.
  • Based on Route of Administration, market is studied across Oral, Parenteral, and Topical.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Application, market is studied across Arthritis, Erythrodermic, Guttate, Intertriginous, Nail, Plaque, and Pustular.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of psoriasis
      • 5.1.1.2. Rising geriatric population coupled with growing prevalence of plaque psoriasis and psoriatic arthritis
      • 5.1.1.3. Ease of process of approval of psoriasis drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Increase in psoriasis research and pipeline drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects of the medication
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Psoriasis Drugs Market, by Therapeutic Class

  • 6.1. Introduction
  • 6.2. Interleukin Inhibitors
  • 6.3. Tumor Necrosis Factor Inhibitor

7. Psoriasis Drugs Market, by Type of Treatment

  • 7.1. Introduction
  • 7.2. Biologic Drugs
  • 7.3. Small Molecule Systemic Drugs
  • 7.4. Tropical Therapies

8. Psoriasis Drugs Market, by Mechanism of Action

  • 8.1. Introduction
  • 8.2. Interleukin Inhibitors
  • 8.3. PDE4 Inhibitors
  • 8.4. TNF Alpha Inhibitors

9. Psoriasis Drugs Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Oral
  • 9.3. Parenteral
  • 9.4. Topical

10. Psoriasis Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Psoriasis Drugs Market, by Application

  • 11.1. Introduction
  • 11.2. Arthritis
  • 11.3. Erythrodermic
  • 11.4. Guttate
  • 11.5. Intertriginous
  • 11.6. Nail
  • 11.7. Plaque
  • 11.8. Pustular

12. Americas Psoriasis Drugs Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Psoriasis Drugs Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Psoriasis Drugs Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca Plc
  • 4. Bausch Health Companies Inc.
  • 5. Celgene Corporation
  • 6. Dr.Reddy's Laboratories
  • 7. Eli Lilly and Company
  • 8. Johnson & Johnson Services, Inc.
  • 9. Leo Pharma AS
  • 10. Merck & Co., Inc.
  • 11. Novartis International AG
  • 12. Pfizer Inc.
  • 13. Stiefel Laboratories Inc.
  • 14. Sun Pharmaceutical Industries Ltd
  • 15. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. PSORIASIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. PSORIASIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. PSORIASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. PSORIASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PSORIASIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PSORIASIS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULE SYSTEMIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TROPICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF ALPHA INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERTRIGINOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 284. PSORIASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 285. PSORIASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023